4 new development(s) in neoantigen vaccines today.
Matteo S. Carlino, MD, PhD, FRACP, explains how the individualized neoantigen therapy V940 is designed and delivered in melanoma. Matteo S. Carlino, MD, PhD, FRACP, a medical oncologist at Westmead and Blacktown Hospitals, a faculty member at Melanoma Institute Australia, and a c…
Personalized mRNA vaccines are showing promise as a new way to fight cancer, particularly melanoma. The vaccines are designed around mutations unique to a patient’s tumor, helping the immune system target cancer cells. While recent trial results are encouraging, researchers say m…
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk. Act now: the analyst who called NVIDIA in 2010 just nam…
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma. The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination …